209 related articles for article (PubMed ID: 27209484)
1. BRAF inhibitor treatment of primary BRAF-mutant ameloblastoma with pathologic assessment of response.
Tan S; Pollack JR; Kaplan MJ; Colevas AD; West RB
Oral Surg Oral Med Oral Pathol Oral Radiol; 2016 Jul; 122(1):e5-7. PubMed ID: 27209484
[TBL] [Abstract][Full Text] [Related]
2. Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma.
Kaye FJ; Ivey AM; Drane WE; Mendenhall WM; Allan RW
J Natl Cancer Inst; 2015 Jan; 107(1):378. PubMed ID: 25475564
[No Abstract] [Full Text] [Related]
3. Neoadjuvant BRAF-targeted therapy for ameloblastoma of the mandible: an organ preservation approach.
Grynberg S; Vered M; Shapira-Frommer R; Asher N; Ben-Betzalel G; Stoff R; Steinberg Y; Amariglio N; Greenberg G; Barshack I; Toren A; Yahalom R; Schachter J; Rechavi G; Hirschhorn A; Abebe Campino G
J Natl Cancer Inst; 2024 Apr; 116(4):539-546. PubMed ID: 37966914
[TBL] [Abstract][Full Text] [Related]
4. Upfront rational therapy in BRAF V600E mutated pediatric ameloblastoma promotes ad integrum mandibular regeneration.
Hirschhorn A; Campino GA; Vered M; Greenberg G; Yacobi R; Yahalom R; Barshack I; Toren A; Amariglio N; Rechavi G
J Tissue Eng Regen Med; 2021 Dec; 15(12):1155-1161. PubMed ID: 34599642
[TBL] [Abstract][Full Text] [Related]
5. BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature.
Ebeling M; Scheurer M; Sakkas A; Pietzka S; Schramm A; Wilde F
Med Oncol; 2023 Apr; 40(6):163. PubMed ID: 37115331
[TBL] [Abstract][Full Text] [Related]
6. Dabrafenib in an elderly patient with metastatic melanoma and BRAF V600R mutation: a case report.
Casadevall D; Vidal J; Gallardo F; Zuccarino F; Arumí-Uría M; Dalmases A; Bellosillo B; Montagut C
J Med Case Rep; 2016 Jun; 10(1):158. PubMed ID: 27255157
[TBL] [Abstract][Full Text] [Related]
7. Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation.
Fernandes GS; Girardi DM; Bernardes JPG; Fonseca FP; Fregnani ER
BMC Cancer; 2018 Sep; 18(1):887. PubMed ID: 30208863
[TBL] [Abstract][Full Text] [Related]
8. BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy.
Sloot S; Zager JS; Kudchadkar RR; Messina JL; Benedict JJ; Gonzalez RJ; DeConti R; Turner LM; McCardle T; Smalley KS; Weber JS; Sondak VK; Gibney GT
Melanoma Res; 2016 Feb; 26(1):83-7. PubMed ID: 26731560
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical analysis of BRAF V600E mutation in ameloblastomas.
do Canto AM; da Silva Marcelino BMR; Schussel JL; Wastner BF; Sassi LM; Corrêa L; de Freitas RR; Hasséus B; Kjeller G; Junior CAL; Braz-Silva PH
Clin Oral Investig; 2019 Feb; 23(2):779-784. PubMed ID: 29855709
[TBL] [Abstract][Full Text] [Related]
10. High frequency of BRAF V600E mutations in ameloblastoma.
Kurppa KJ; Catón J; Morgan PR; Ristimäki A; Ruhin B; Kellokoski J; Elenius K; Heikinheimo K
J Pathol; 2014 Apr; 232(5):492-8. PubMed ID: 24374844
[TBL] [Abstract][Full Text] [Related]
11. Activating FGFR2-RAS-BRAF mutations in ameloblastoma.
Brown NA; Rolland D; McHugh JB; Weigelin HC; Zhao L; Lim MS; Elenitoba-Johnson KS; Betz BL
Clin Cancer Res; 2014 Nov; 20(21):5517-26. PubMed ID: 24993163
[TBL] [Abstract][Full Text] [Related]
12. An immunohistochemical and genetic study of BRAF
Seki-Soda M; Sano T; Ito K; Yokoo S; Oyama T
Pathol Int; 2020 Apr; 70(4):224-230. PubMed ID: 31930640
[TBL] [Abstract][Full Text] [Related]
13. Genetic Study of
Kokubun K; Yamamoto K; Akashi Y; Chujo T; Nakajima K; Matsuzaka K
Int J Surg Pathol; 2022 Jun; 30(4):378-384. PubMed ID: 34994576
[No Abstract] [Full Text] [Related]
14. Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma.
Schmid S; Siano M; Joerger M; Rodriguez R; Müller J; Früh M
Lung Cancer; 2015 Jan; 87(1):85-7. PubMed ID: 25466451
[TBL] [Abstract][Full Text] [Related]
15. Dabrafenib in the treatment of advanced melanoma.
Medina T; Amaria MN; Jimeno A
Drugs Today (Barc); 2013 Jun; 49(6):377-85. PubMed ID: 23807941
[TBL] [Abstract][Full Text] [Related]
16. BRAF V600E expression in ameloblastomas-A 36-patient cohort from Helsinki University Hospital.
Kelppe J; Thorén H; Ristimäki A; Haglund C; Sorsa T; Hagström J
Oral Dis; 2019 May; 25(4):1169-1174. PubMed ID: 30811720
[TBL] [Abstract][Full Text] [Related]
17. Dabrafenib Treatment in a Patient with an Epithelioid Glioblastoma and BRAF V600E Mutation.
Ceccon G; Werner JM; Dunkl V; Tscherpel C; Stoffels G; Brunn A; Deckert M; Fink GR; Galldiks N
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29621181
[TBL] [Abstract][Full Text] [Related]
18. Dabrafenib.
Kainthla R; Kim KB; Falchook GS
Recent Results Cancer Res; 2014; 201():227-40. PubMed ID: 24756796
[TBL] [Abstract][Full Text] [Related]
19. Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies.
Gibney GT; Zager JS
Expert Opin Drug Metab Toxicol; 2013 Jul; 9(7):893-9. PubMed ID: 23621583
[TBL] [Abstract][Full Text] [Related]
20. A turning point in therapy for ameloblastomas.
Abe M; Zong L; Abe T; Hoshi K
Oral Oncol; 2018 May; 80():95-96. PubMed ID: 29548681
[No Abstract] [Full Text] [Related]
[Next] [New Search]
